Amelioration of apomorphine adverse effects

• US 5,994,363 A
• Filed: 08/24/1998
• Issued: 11/30/1999
• Est. Priority Date: 08/24/1998
• Status: Expired due to Fees

• Current Assignee: Pentech Pharmaceuticals Incorporated
• Original Assignee: Pentech Pharmaceuticals Incorporated
• Inventors: El-Rashidy, Ragab, Ronsen, Bruce
• Primary Examiner(s): Reamer, James H.
• Application Number:
  US09/138,982
• Time in Patent Office: 463 Days
• Field of Search: 514/284
• US Class Current: 514/284
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/22 Anxiolytics

Abstract

Symptoms of Parkinson'"'"'s disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects.

Claims

1. A method of minimizing adverse effects of apomorphine on a human patient comprising the steps of:

(a) administering to a human patient a threshold dose of about 2 to about 8 mg of apomorphine;

(b) administering to the human patient a series of increasing periodic doses of apomorphine greater than the threshold dose until a final apomorphine dose in excess of a therapeutic dose has been received by the human patient; and

thereafter

(c) administering to the human patient a therapeutic dose of apomorphine.

2. The method of claim 1 wherein the step of administering a series of increasing doses occurs at a rate of one dose per day for at least two days.

3. The method of claim 1 wherein the therapeutic dose of apomorphine is an amount sufficient to induce a penile erection sufficient for vaginal penetration.

4. The method of claim 1 wherein the therapeutic dose of apomorphine is an amount sufficient to ameliorate sexual dysfunction in a female patient by inducing clitoral erectogenesis and vaginal engorgement on stimulation of the female patient.

5. The method of claim 1 wherein the apomorphine is administered as a suppository.

6. The method of claim 1 wherein the apomorphine is administered transdermally.

7. The method of claim 1 wherein the apomorphine is administered by subcutaneous injection.

8. A method of minimizing adverse effects of apomorphine on a male patient comprising the steps of:

(a) administering to the male patient a sublingual threshold dose of apomorphine;

(b) administering to the male patient a series of increasing sublingual doses of apomorphine greater than the threshold dose until a final sublingual apomorphine dose in excess of that needed to produce a penile erection sufficient for penetration has been received by the male patient; and

(c) administering to the male patient, prior to sexual activity, a sublingual therapeutic dose of apomorphine less than the final dose but sufficient to produce an erection adequate for penetration without attendant substantial adverse effects.

9. The method of claim 8 wherein the step of administering a series of increasing doses occurs at a rate of one dose per day for at least three days.

10. The method of claim 8 further comprising the step of maintaining an apomorphine concentration in the male patient'"'"'s plasma within the range of about 0.3 to about 5.5 nanograms per milliliter during sexual activity.

11. The method of claim 8 further comprising the step of maintaining an apomorphine concentration in the male patient'"'"'s plasma preferably within the range of about 0.3 to about 4 nanograms per milliliter during sexual activity.

12. The method of claim 8 further comprising the step of maintaining an apomorphine concentration in the male patient'"'"'s plasma within the range of about 1 to about 2 nanograms per milliliter during sexual activity.

13. The method of claim 8 wherein the sublingual threshold dose of apomorphine is in the range of about 2 mg to about 8 mg.

14. The method of claim 8 wherein the sublingual therapeutic dose is in the range of about 35 to about 74 micrograms per kilogram of patient'"'"'s body weight.

15. The method of claim 8 wherein the final sublingual dose of apomorphine is within the range of about 8 to about 10 mg.

16. The method of claim 8 wherein the sublingual therapeutic dose is in the range of about 50 to about 74 micrograms per kilogram of patient'"'"'s body weight.

17. A method for amelioration of social phobia of a human patient, comprising the steps of:

(a) administering to the human patient a threshold dose of apomorphine;

(b) administering to the human patient a series of increasing periodic doses of apomorphine greater than the threshold dose until a final apomorphine dose in excess of a therapeutic dose of apomorphine has been received by the human patient, the therapeutic dose being an amount sufficient to reduce symptoms of social phobia; and

thereafter

(c) administering to the human patient the therapeutic dose of apomorphine.

18. The method of claim 17 wherein the therapeutic dose is administered to provide a patient'"'"'s plasma concentration of apomorphine of about 5 to about 8 nanograms per milliliter.

19. A method of minimizing adverse effects of apomorphine on a human patient comprising the steps of:

administering to the human patient a threshold dose of apomorphine;

administering to the human patient a series of increasing doses of apomorphine greater than the threshold dose until a final sublingual apomorphine dose in excess of that needed to ameliorate Parkinsonism symptoms has been received by the human patient; and

thereafter

administering to the human patient a therapeutic dose of apomorphine less than the final dose but sufficient to ameliorate Parkinsonism symptoms without attendant substantial adverse effects.

20. The method of claim 19 wherein the therapeutic dose of apomorphine is administered subcutaneously in the range of about 3 to about 8 milligrams.

21. The method of claim 19 wherein the therapeutic dose of 5 apomorphine is administered in a sublingual dosage form containing apomorphine in the range of about 10 to about 60 milligrams.

22. The method of claim 19 wherein the threshold dose of apomorphine is administered subcutaneously in a dosage form containing apomorphine in the range of about 1 to about 5 milligrams.

23. The method of claim 19 further comprising the step of maintaining an apomorphine concentration in the patient'"'"'s plasma within the range of about 3 to about 20 nanograms per milliliter.